ATE513563T1 - Therapeutische und toleranz-induzierende antikörper - Google Patents
Therapeutische und toleranz-induzierende antikörperInfo
- Publication number
- ATE513563T1 ATE513563T1 AT01974480T AT01974480T ATE513563T1 AT E513563 T1 ATE513563 T1 AT E513563T1 AT 01974480 T AT01974480 T AT 01974480T AT 01974480 T AT01974480 T AT 01974480T AT E513563 T1 ATE513563 T1 AT E513563T1
- Authority
- AT
- Austria
- Prior art keywords
- therapeutic
- protein
- tolerance
- inducing antibodies
- therapeutic target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70592—CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0024673.6A GB0024673D0 (en) | 2000-10-09 | 2000-10-09 | Therapeutic antibodies |
US24214300P | 2000-10-23 | 2000-10-23 | |
PCT/GB2001/004518 WO2002030460A2 (en) | 2000-10-09 | 2001-10-09 | Therapeutic antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE513563T1 true ATE513563T1 (de) | 2011-07-15 |
Family
ID=26245125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01974480T ATE513563T1 (de) | 2000-10-09 | 2001-10-09 | Therapeutische und toleranz-induzierende antikörper |
Country Status (8)
Country | Link |
---|---|
US (4) | US8623357B2 (de) |
EP (1) | EP1324771B2 (de) |
JP (2) | JP4334866B2 (de) |
AT (1) | ATE513563T1 (de) |
AU (2) | AU9399501A (de) |
CA (1) | CA2423850C (de) |
ES (1) | ES2368387T5 (de) |
WO (1) | WO2002030460A2 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU9399501A (en) * | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
US20040109855A1 (en) * | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
KR20060002896A (ko) * | 2003-03-31 | 2006-01-09 | 기린 비루 가부시키가이샤 | 항 cd52 항체에 의한 조절성 t 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물 |
BRPI0416141B8 (pt) | 2003-11-01 | 2021-05-25 | Biovation Ltd | anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina |
CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
AU2016213702C1 (en) * | 2007-08-22 | 2018-11-29 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
AU2013202755B2 (en) * | 2007-08-22 | 2016-05-12 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
AU2010215761B2 (en) | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
EP2750690B1 (de) | 2011-11-15 | 2018-11-07 | The Walter and Eliza Hall Institute of Medical Research | Löslicher mediator |
WO2013163631A2 (en) | 2012-04-27 | 2013-10-31 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
PE20150643A1 (es) | 2012-06-22 | 2015-05-29 | Cytomx Therapeutics Inc | Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos |
US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
WO2014052462A2 (en) | 2012-09-25 | 2014-04-03 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
SG11201503843VA (en) | 2012-11-15 | 2015-06-29 | Inst Medical W & E Hall | Soluble mediator |
RU2015132436A (ru) | 2013-01-04 | 2017-02-09 | Сайтомкс Терапьютикс, Инк. | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
CA2908380A1 (en) | 2013-04-09 | 2014-10-16 | Boston Biomedical, Inc. | Methods for treating cancer |
EP4067383A1 (de) | 2013-07-25 | 2022-10-05 | Cytomx Therapeutics Inc. | Multispezifische antikörper, aktivierbare multispezifische antikörper und verfahren zur verwendung davon |
KR20230011497A (ko) | 2013-09-25 | 2023-01-20 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
CN114106099B (zh) | 2014-01-31 | 2024-05-24 | 西托姆克斯治疗公司 | 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 |
US20150333068A1 (en) * | 2014-05-14 | 2015-11-19 | Globalfoundries Singapore Pte. Ltd. | Thyristor random access memory |
CN107108738A (zh) | 2014-07-25 | 2017-08-29 | 西托姆克斯治疗公司 | 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法 |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
PT3292150T (pt) | 2015-05-04 | 2020-06-01 | Cytomx Therapeutics Inc | Anticorpos anti-cd166 ativáveis e os seus métodos de utilização |
TWI726879B (zh) | 2015-05-04 | 2021-05-11 | 美商Cytomx生物製藥公司 | 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法 |
AU2016271475A1 (en) | 2015-06-03 | 2017-12-21 | Boston Biomedical, Inc. | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
US11117968B2 (en) | 2016-11-03 | 2021-09-14 | Bristol-Myers Squibb Company | Activatable anti-CTLA-4 antibodies and uses thereof |
US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル, インコーポレイテッド | がんを処置するための方法 |
JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗pdl1抗体、およびその使用方法 |
EP3652210A1 (de) | 2017-07-14 | 2020-05-20 | CytomX Therapeutics, Inc. | Anti-cd166-antikörper und verwendungen davon |
US11623965B2 (en) | 2017-08-16 | 2023-04-11 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
KR20200064096A (ko) | 2017-10-14 | 2020-06-05 | 싸이톰스 테라퓨틱스, 인크. | 항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법 |
WO2020251878A1 (en) | 2019-06-11 | 2020-12-17 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
EP4133085A1 (de) | 2020-04-10 | 2023-02-15 | CytomX Therapeutics, Inc. | Aktivierbare cytokinkonstrukte und verwandte zusammensetzungen und verfahren |
EP4308594A2 (de) | 2021-03-16 | 2024-01-24 | CytomX Therapeutics, Inc. | Maskierte aktivierbare cytokinkonstrukte und verwandte zusammensetzungen und verfahren |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
US5686600A (en) | 1994-06-28 | 1997-11-11 | Novartis Finance Corporation | Antibodies which bind to insect gut proteins and their use |
GB9603507D0 (en) * | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
WO1998011126A1 (de) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs |
US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
CA2408103A1 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds and methods of making and using the same |
WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
AU2003265866A1 (en) | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
EP1993608A1 (de) | 2006-03-10 | 2008-11-26 | Diatos | Über einen enzym-spaltbaren linker an einen antikörper konjugierte arzneimittel gegen krebs |
CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
-
2001
- 2001-10-09 AU AU9399501A patent/AU9399501A/xx active Pending
- 2001-10-09 AU AU2001293995A patent/AU2001293995B2/en not_active Expired
- 2001-10-09 ES ES01974480T patent/ES2368387T5/es not_active Expired - Lifetime
- 2001-10-09 CA CA2423850A patent/CA2423850C/en not_active Expired - Lifetime
- 2001-10-09 EP EP01974480.4A patent/EP1324771B2/de not_active Expired - Lifetime
- 2001-10-09 WO PCT/GB2001/004518 patent/WO2002030460A2/en active IP Right Grant
- 2001-10-09 AT AT01974480T patent/ATE513563T1/de not_active IP Right Cessation
- 2001-10-09 JP JP2002533899A patent/JP4334866B2/ja not_active Expired - Lifetime
-
2008
- 2008-12-11 JP JP2008315168A patent/JP5847370B2/ja not_active Expired - Lifetime
- 2008-12-15 US US12/316,621 patent/US8623357B2/en not_active Expired - Lifetime
-
2013
- 2013-07-31 US US13/955,785 patent/US20140212418A1/en not_active Abandoned
-
2015
- 2015-12-18 US US14/974,042 patent/US10800850B2/en not_active Expired - Lifetime
-
2020
- 2020-10-12 US US17/068,538 patent/US20210269544A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170137529A1 (en) | 2017-05-18 |
JP5847370B2 (ja) | 2016-01-20 |
JP2009108093A (ja) | 2009-05-21 |
US20210269544A1 (en) | 2021-09-02 |
CA2423850C (en) | 2017-07-04 |
EP1324771B1 (de) | 2011-06-22 |
CA2423850A1 (en) | 2002-04-18 |
JP2004510827A (ja) | 2004-04-08 |
ES2368387T5 (es) | 2019-03-07 |
ES2368387T3 (es) | 2011-11-16 |
US20140212418A1 (en) | 2014-07-31 |
US20100015166A1 (en) | 2010-01-21 |
JP4334866B2 (ja) | 2009-09-30 |
AU2001293995B2 (en) | 2005-10-13 |
US8623357B2 (en) | 2014-01-07 |
WO2002030460A2 (en) | 2002-04-18 |
US10800850B2 (en) | 2020-10-13 |
WO2002030460A3 (en) | 2003-03-13 |
AU9399501A (en) | 2002-04-22 |
EP1324771A2 (de) | 2003-07-09 |
EP1324771B2 (de) | 2018-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE513563T1 (de) | Therapeutische und toleranz-induzierende antikörper | |
DE60327205D1 (de) | Therapeutische antiköper mit reduzierten nebenwirkungen | |
MY169272A (en) | Her2 antibody composition | |
CY1110783T1 (el) | Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων | |
DK1534335T3 (da) | FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf | |
NO20016007D0 (no) | Rekombinant anti-CD40-antistoff og anvendelser derav | |
NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
EA201300022A1 (ru) | Терапевтическое человеческое моноклональное антитело против il-1r1 | |
DK1572748T3 (da) | Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2 | |
ATE476992T1 (de) | Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper | |
ATE497392T1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
EA200601603A1 (ru) | Миметические антитела glp-1 человека, композиции, способы и применения | |
WO2006122257A3 (en) | Nebulization of monoclonal antibodies for treating pulmonary diseases | |
UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
NO20060843L (no) | RG1-antistoffer og anvendelser derav | |
CY1109817T1 (el) | Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου | |
DE69738138D1 (de) | Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers | |
ATE433327T1 (de) | Chemisch programmierbare immunität | |
WO2020076789A3 (en) | Combinations of anti-staphylococcus aureus antibodies | |
AU6819600A (en) | Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections | |
TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
WO2003072727A3 (en) | EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER | |
DE60109922D1 (de) | Therapeutische verbindungen gegen eierstockkrebs | |
WO2006002195A3 (en) | Method of complexing a protein by the use of a dispersed system and proteins thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |